Published in Blood Weekly, June 17th, 1996
The study also offered tantalizing evidence that CD4 percentages declined more slowly in vaccine recipients than in controls.
Nearly all of the asymptomatic subjects, who had CD4+ T-cell counts of at least 400 cells/(mu)L, developed proliferative lymphocyte responses to the vaccine immunogen.
But responses were also seen to other relevant epitopes: a third of the subjects developed lymphocyte-proliferative responses to a different HIV envelope protein, and more than half responded to p24 and p66 HIV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (1996-06-17)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.